| Literature DB >> 30414169 |
Xinhui Fu1,2,3, Yan Huang3, Xinjuan Fan3, Yanhong Deng4, Huanliang Liu1,2, Hongzhi Zou1,2, Peihuang Wu1,2, Zhiting Chen1,2,3, Jinglin Huang1,2,3, Jingxuan Wang1,2, Hanjie Lin1,2,3, Shuhui Huang3, Xiaoli Tan1,2,3, Ping Lan1,5, Lei Wang5, Jian-Ping Wang1,2.
Abstract
The incidence of colorectal cancer (CRC) is increasing in China. Here, we aimed to evaluate the latest demographic trends and KRAS/BRAF mutations status of Chinese CRC. Five thousand five hundred and forty-six CRC patients diagnosed from 2010 to 2017 were involved. KRAS exon 2 and BRAFV600E mutations were detected by Sanger sequencing and high-resolution melting analysis or allelic-specific probe method. Gene mutation profiles and clinicopathologic characteristics of 5495 patients were analyzed. The joinpoint regression model was used to predict the demographic data in 2018. We found KRAS exon 2 and BRAFV600E mutation rates were 37.7 and 2.8% in CRC patients. Tumors with KRAS exon 2 mutations were more likely to be present in female and patients aged older than 75 years, right colon and have well-differentiated histology. Tumors with BRAFV600E mutations were more likely to be present in the female, right colon and have poorly differentiated histology. From 2010 to 2017, the percentage of colon cancer and tubular adenocarcinoma in CRC increased substantially (from 39.3 to 51.8%, from 78.6 to 93.4%, respectively). The percentage of right colon cancer increased from 18.3 to 20.5%, which predictively may keep at 22.6% in 2018. The rise trends for patients with moderate differentiation tumor or KRAS exon 2 mutated tumor were apparent (from 50.3 to 78.6%, from 32.8 to 39.7%, respectively). In conclusion, in recent 8 years, there is a shift to the colon, especially right colon in the incidence of Chinese CRC. Moreover tubular adenocarcinoma is becoming the primary histology type.Entities:
Keywords: zzm321990BRAF mutation; zzm321990KRAS mutation; colorectal cancer; demographic trends; tubular adenocarcinoma
Mesh:
Substances:
Year: 2019 PMID: 30414169 DOI: 10.1002/ijc.31973
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396